Chicago, ILNCT07359820Now EnrollingIRB Ready

FGFR2 Gene Fusion/Rearrangement Clinical Trial in Chicago, IL

Access cutting-edge fgfr2 gene fusion/rearrangement treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Elevar Therapeutics

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access fgfr2 gene fusion/rearrangement specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related fgfr2 gene fusion/rearrangement treatment provided free

Apply for This Chicago Location

Check if you qualify for this fgfr2 gene fusion/rearrangement clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This FGFR2 Gene Fusion/Rearrangement Study in Chicago

The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement. Participants will: * Take lirafugratinib regularly as instructed by their study doctor. * Visit the clinic as instructed for checkups and tests. * Keep a diary recording each time a dose of lirafugratinib is taken.

Sponsor: Elevar Therapeutics

Who Can Participate

Inclusion Criteria

Unresectable, locally advanced, or metastatic solid tumor (other than CCA).
Documented FGFR2 gene fusion or rearrangement per local testing of blood and/or tumor.
Patient must have measurable disease per RECIST v1.1• Patient has ECOG performance status of 0-1.
Previously (\>30 days) treated with ≥1 line of systemic therapy including chemotherapy (e.g., gemcitabine/cisplatin), immunotherapy, radiation therapy, or other approved therapies.
Subject has not received prior treatment with an FGFRi.

Exclusion Criteria

An uncontrolled comorbidity.
Patient does not have adequate organ function (defined in protocol).
Patient has active infection, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV) (defined in protocol). Patients with well-controlled HBV are eligible (defined in protocol).
QT interval corrected using Fridericia's formula (QTcF) \> 480 msec or history of prolonged QT syndrome, Torsades de pointes or familial history of prolonged QT syndrome.
Clinically significant, uncontrolled cardiovascular disease.
CNS metastases or primary CNS tumor that is associated with progressive neurologic symptoms.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT07359820) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

FGFR2 Gene Fusion/Rearrangement Treatment Options in Chicago, IL

If you're searching for fgfr2 gene fusion/rearrangement treatment options in Chicago, IL, this clinical trial (NCT07359820) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced fgfr2 gene fusion/rearrangement specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all fgfr2 gene fusion/rearrangement clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Chicago, IL

See all rheumatoid arthritis clinical trials recruiting in Chicago — not just this study.

Browse Rheumatoid Arthritis Trials in Chicago →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL